Phase I, open‐label, single‐dose study in adult men without HIV infection assessing the pharmacokinetics of Islatravir in plasma and ISL‐TP in peripheral blood mononuclear cell following single oral dose administration of 20 mg Islatravir
Latest Information Update: 25 Apr 2022
At a glance
- Drugs Islatravir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- 25 Apr 2022 New trial record
- 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics